Skip to main content
SpringerLink
Log in

Expression of bone sialoprotein and osteopontin in breast cancer bone metastases

  • Published:
Clinical & Experimental Metastasis Aims and scope Submit manuscript

Abstract

Bone sialoprotein (BSP) and osteopontin (OPN) are prominent, mineral-associated proteins in the extracellular matrix of bone that have been implicated in the metastatic activity of cancer cells. The expression of BSP, which is normally restricted to mineralizing tissues, has been observed in cancers with a high propensity for forming bone metastases. To investigate the relationship between BSP expression and the formation of bone metastases we have conducted an initial study of the expression of BSP in 10 intraductal breast carcinoma bone metastases using immunostaining and in situ hybridization, and compared the expression with OPN. The metastases were characterized by the infiltration of tumour cells into bone with extensive bone resorption evident. Moderate to strong staining for BSP was observed in all (100%) carcinomas, which also expressed BSP mRNA as determined by in situ hybridization. Variable staining for BSP was also observed in the mineralized bone and expression of BSP mRNA could be observed in osteoblastic cells on the bone surface and in some osteocytes at sites of bone remodelling. Contrary to a previous report, BSP expression could be demonstrated by PCR in three breast cancer cell lines, MCF-7, T47-D and MDA-MB-231. Moreover, in sub-cutaneous tumours formed by MDA-MB-231 breast cancer cells injected into athymic mice, higher immunostaining for BSP was seen in large ulcerating tumours in which mineral deposits were formed. In contrast to BSP, staining for OPN in bone metastases was generally restricted to the interface between tumor cells and bone surface of the carcinomas. While OPN staining was also observed in the cytoplasm of osteoclasts, which showed strong hybridization to a digoxygenin-labelled OPN cRNA probe, expression of OPN was not clearly detectable in the tumour cells. These studies provide the first demonstration of BSP expression by tumour cells in bone metastases and support the concept that BSP may have a role in targeting metastatic cells to bone. Expression of OPN in bone metastases appears to be related to increased bone resorptive activity by osteoclasts.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Jacob K, Webber M, Benayahu D et al. Osteonectin promotes prostate cancer cell migration and invasion. A possible mechanism for metastasis to bone. Cancer Res 1999; 59: 4453–7.

    PubMed  CAS  Google Scholar 

  2. Brown LF, Papadopoulos-Sergiou A, Berse B et al. Osteopontin expression and distribution in human carcinomas. Am J Path 1994; 145: 610–23.

    PubMed  CAS  Google Scholar 

  3. Oates AJ, Barraclough R, Rudland PS. The role of osteopontin in tumorigenesis and metastasis. Invasion & Metastasis 1997; 17: 1–5.

    CAS  Google Scholar 

  4. Bellahcène A, Castronovo V. Increased expression of osteonectin and osteopontin, two bone matrix proteins, in human breast cancer. Am J Pathol 1995; 146: 95–100.

    PubMed  Google Scholar 

  5. Bellahcène A, Kroll M, Liebens F et al. Bone sialoprotein expression in primary human breast cancer is associated with bone metastases development. J Bone Miner Res 1996; 11: 665–70.

    PubMed  Google Scholar 

  6. Bellahcène A, Maloujahmoum N, Fisher LW et al. Expression of bone sialoprotein in human lung cancer. Calcif Tissue Int 1997; 61: 183–8.

    Article  PubMed  Google Scholar 

  7. Hirota S, Ito A, Nagoshi J et al. Expression of bone matrix protein messenger ribonucleic acids in human breast cancers. Possible involvement of osteopontin in development of calcifying foci. Lab Invest 1995; 72: 64–9.

    PubMed  CAS  Google Scholar 

  8. Gillespie MT, Thomas RJ, Pu ZY et al. Calcitonoin receptors, bone sialoprotein and osteopontin are expressed in primary breast tumours. Int J Cancer 1997; 73: 812–5.

    Article  PubMed  CAS  Google Scholar 

  9. Waltregny D, Bellahcène A, Van Riet I et al. Prognostic value of bone sialoprotein expression in clinically localized human prostate cancer. J Natl Cancer Inst 1998; 90: 1000–8.

    Article  PubMed  CAS  Google Scholar 

  10. Sharp JA, Sung V, Slavin J et al. Tumor cells are the source of osteopontin and bone sialoprotein expression in human breast cancer. Lab Invest 1999; 79: 869–77.

    PubMed  CAS  Google Scholar 

  11. Delmas PD, Malaval L. The proteins of bone. In Mundy GR, Martin TJ (eds): Handbook of Experimental Pharmacology, 107: Physiology and Pharmacology of Bone, 1993; 673-724.

  12. Ganss B, Kim RH, Sodek J. Bone sialoprotein. Crit Revs Oral Biol & Med 1999; 10: 79–98.

    CAS  Google Scholar 

  13. Sodek J, Ganss B, McKee MD. Osteopontin. Crit Revs. Oral Biol. & Med., 2000; 11: 279–303.

    Article  CAS  Google Scholar 

  14. Rosol TJ. Pathogenesis of bone metastases: Role of tumor-related proteins. J Bone Miner Res 2000; 15: 844–50.

    Article  PubMed  CAS  Google Scholar 

  15. Oldberg A, Franzén A, Heinegärd D. The primary structure of bone sialoprotein. J Biol Chem 1988; 263: 19430–2.

    PubMed  CAS  Google Scholar 

  16. Fisher LW, McBride OW, Termine JD et al. Human bone sialoprotein. Deduced protein sequence and chromosomal localization. J Biol Chem 1990; 265: 2347–51.

    PubMed  CAS  Google Scholar 

  17. Chen J, Shapiro H S, Sodek J. Developmental expression of bone sialoprotein mRNA in rat mineralized connective tissues. J Bone Miner Res 1992; 7: 987–97.

    PubMed  CAS  Google Scholar 

  18. MacNeil RL, Sheng N, Strayhorn C et al. Bone sialoprotein is localized to the root surface during cementogenesis. J Bone Min Res 1994; 9: 1597–606.

    CAS  Google Scholar 

  19. Bellahcène A, Merville M-P, Castronovo V. Expression of bone sialoprotein, a bone matrix protein, in human breast cancer. Cancer Res 1994; 54: 2833–26.

    Google Scholar 

  20. Bellahcène A, Menard S, Bufalino R et al. Expression of bone sialoprotein in primary human breast cancer is associated with poor survival. Int J Cancer 1996; 69: 350–3.

    Article  PubMed  Google Scholar 

  21. Bellahcène A, Antoine N, Clausse N et al. Detection of bone sialoprotein in human breast cancer tissue and cell lines at both protein and messenger ribonucleic acid levels. Lab Invest 1996; 75: 203–10.

    PubMed  Google Scholar 

  22. Castronovo V, Bellahcène A. Evidence that breast cancer associated microcalcifications are mineralized malignant cells. Int J Oncol 1998; 12: 305–8.

    PubMed  CAS  Google Scholar 

  23. Withold W, Armbruster FP, Karmatschek M et al., Bone sialoprotein in serum of patients with malignant bone-diseases. Clinical Chem 1997; 43: 85–91.

    CAS  Google Scholar 

  24. Diel IJ, Solomayer EF, Seibel MJ et al. Serum bone sialoprotein in patients with primary breast cancer is a prognostic marker for subsequent bone metastasis. Clin Cancer Res 1999; 5: 3914–9.

    PubMed  CAS  Google Scholar 

  25. Singhal H, Bautista DS, Tonkin KS et al. Elevated plasma osteopontin in metastatic breast cancer associated with increased tumor burden and decreased survival. Clin Cancer Res 1997; 3: 605–11.

    PubMed  CAS  Google Scholar 

  26. Tuck AB, O'Malley FP, Singhal H et al. Osteopontin and p53 expression are associated with tumor progression in a case of synchronous, bilateral invasive mammary carcinomas. Arch Pathol Lab Med 1997; 121: 578–84.

    PubMed  CAS  Google Scholar 

  27. Denhardt DT, Guo X. Osteopontin: A protein with diverse functions. FASEB J 1993; 7: 1475–82.

    PubMed  CAS  Google Scholar 

  28. Denhardt DT, Chambers AF. Overcoming obstacles to metastasis-defenses against host defenses: Osteopontin (OPN) as a shield against attack by cytotoxic host cells. J Cell Biochem 1994; 56: 48–51.

    Article  PubMed  CAS  Google Scholar 

  29. Crawford HC, Matrisian LM, Liaw L. Distinct roles of osteopontin in host defense activity and tumor survival during squamous cell carcinoma progression in vivo. Cancer Res 1998; 58: 5206–15.

    PubMed  CAS  Google Scholar 

  30. Scatena M, Almeida M, Chaisson ML et al. NFkB mediates alphavbeta3 integrin-induced endothelial cell survival. J Cell Biol 1998; 141: 1083–93.

    Article  PubMed  CAS  Google Scholar 

  31. Fedarko NS, Fohr B, Robey PG et al., Factor H binding to bone sialoprotein and osteopontin enables tumor evasion of complement mediated attack. J Biol Chem 2000; 275: 16666–672.

    Article  PubMed  CAS  Google Scholar 

  32. Shiraga H, Min W, VanDusen WJ et al. Inihibition of calcium oxalate crystal growth in vitro by uropontin: Another member of the aspartic acid-rich protein superfamily. Proc Natl Acad Sci USA 1992; 89: 426–30.

    Article  PubMed  CAS  Google Scholar 

  33. Fisher LW, Stubbs JT, Young MF. Antisera and CDNA probes to human and certain animal model bone matrix noncollagenous proteins. Acta Orthop Scand 1995; 66 (Suppl 266): 61–5.

    Google Scholar 

  34. Waltregny D, Bellahcène A, de Leval X et al. Increased expression of bone sialoprotein in bone metastases compared to visceral metastases in human breast and prostate cancers. J Bone Miner Res 2000; 15: 834–43.

    Article  PubMed  CAS  Google Scholar 

  35. Stewart JF, King RGB, Sexton SA et al., Oestrogen receptors, site of metastastic disease and survival in recurrent breast cancer. Eur J Cancer 1981; 17: 449–53.

    PubMed  CAS  Google Scholar 

  36. Orr WF, Kostenuik P, Sanchez-Sweatman OH et al. Mechanisms involved in the metastasis of cancer to bone. Breast Cancer Res Treat 1993; 25: 151–63.

    Article  PubMed  CAS  Google Scholar 

  37. Yoneda T, Sasaki A, Mundy GR. Osteolytic bone disease in breast cancer. Breast Cancer Res Treat 1994; 32: 73–84.

    Article  PubMed  CAS  Google Scholar 

  38. Sasaguri K, Ganss B, Sodek J et al. Expression of bone sialoprotein in mineralized tissues of tooth and bone and in buccal-pouch carcinomas of Syrian golden hamsters. Arch Oral Biol 2000; 45: 551–62.

    Article  PubMed  CAS  Google Scholar 

  39. Bosse A, Wuisman P, Jones DB et al. Noncollagenous proteins in heterotopic ossification. Immunohistochemical analysis in 15 paraplegics. Acta Orthop Scand 1993; 64: 634–8.

    Article  PubMed  CAS  Google Scholar 

  40. McKee MD, Giachelli CM, Nanci A. Matrix-mineral relationships in calcifying human atherosclerotic plaque: Ultrastructural immunodetection of osteopontin and bone sialoprotein at calcification sites. J Bone Miner Res 1996; 11: S330.

    Article  Google Scholar 

  41. Contri MB, Boraldi F, Taparelli F et al. Matrix proteins with high affinity for calcium ions are associated with mineralization within the elastic fibers of pseudoxanthoma elasticum dermis. Am J Pathol 1996; 148: 569–77.

    PubMed  CAS  Google Scholar 

  42. Hunter GK, Goldberg HA. Nucleation of hydroxyapatite by bone sialoprotein. Proc Natl Acad Sci USA 1993; 90: 8562–5.

    Article  PubMed  CAS  Google Scholar 

  43. Oldberg A, Franzèn A, Heinegärd D et al. Identification of a bone sialoprotein receptor in osteosarcoma cells. J Biol Chem 1988; 263: 19433–6.

    PubMed  CAS  Google Scholar 

  44. Varner JA, Cheresh DA. Integrins and Cancer. Curr Opin Cell Biol 1996; 8: 724–30.

    Article  PubMed  CAS  Google Scholar 

  45. Fang F, Orend G, Watanabe N et al. Dependence of cyclin E-CDK2 kinase activity on cell anchorage. Science 1996; 271: 499–502.

    PubMed  CAS  Google Scholar 

  46. Ashkar S, Weber GF, Panoutsakopoulou V et al. Eta-1 (osteopontin): an early component of type-1 (cell mediated) immunity. Science 2000; 287: 860–4.

    Article  PubMed  CAS  Google Scholar 

  47. Hunter GK, Hauschka PV, Poole AR et al. Nucleation and inhibition of hydroxyapatite formation by mineralized tissue proteins. Biochem J 1996; 317 (Pt 1): 59–64.

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Medical Research Council Group in Periodontal Physiology, Canada

    Tharwat Ibrahim, Iona Leong, Howard C. Tenenbaum, Bernard Ganss & Sela Cheifetz

  2. Ontario Cancer Institute, Toronto, Ontario, Canada

    Otto Sanchez-Sweatman & Rama Khokha

  3. Department of Biochemistry, Faculties of Dentistry and Medicine, University of Toronto, Canada

    Jaro Sodek

Authors
  1. Tharwat Ibrahim
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Iona Leong
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Otto Sanchez-Sweatman
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Rama Khokha
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Jaro Sodek
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Howard C. Tenenbaum
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Bernard Ganss
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Sela Cheifetz
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Ibrahim, T., Leong, I., Sanchez-Sweatman, O. et al. Expression of bone sialoprotein and osteopontin in breast cancer bone metastases. Clin Exp Metastasis 18, 253–260 (2000). https://doi.org/10.1023/A:1006754605901

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1023/A:1006754605901

Search

Navigation